Advanced search
Publication Cover
Postgraduate Medicine Volume 133, 2021 - Issue 6
Submit an article Journal homepage
6,637
Views
22
CrossRef citations to date
0
Altmetric
Clinical features - Review

EPA’s pleiotropic mechanisms of action: a narrative review

John R. Nelsona California Cardiovascular Institute, Fresno, California, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2455-0296
ORCID Icon,
Matthew J. Budoffb Department of Medicine, Lundquist Institute, Torrance, California, USA
,
Omar R. Wanic Northern Arizona Healthcare Medical Group – Flagstaff, Flagstaff, AZ, USA
,
Viet Led Cardiovascular Research, Intermountain Heart Institute/CV Research, Intermountain Healthcare, Murray, Utah, and Rocky Mountain University of Health Professions, Provo, USAORCID Iconhttps://orcid.org/0000-0001-6659-5332
ORCID Icon,
Dhiren K. Patele Department of Pharmacy Practice, MCPHS University, Boston, MA, USA
,
Ashley Nelsonf Department of Internal Medicine, Saint Agnes Medical Center, Fresno, California, USA
&
Richard L. Nemiroffg Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
 show all
Pages 651-664 | Received 04 Mar 2021, Accepted 21 Apr 2021, Published online: 13 May 2021

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Michael Miller, Lale Tokgozoglu, Klaus G. Parhofer, Yehuda Handelsman, Lawrence A. Leiter, Ulf Landmesser, Eliot A. Brinton & Alberico L. Catapano. (2022) Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. Expert Review of Cardiovascular Therapy 20:8, pages 609-625.
Read now

Articles from other publishers (21)

John R. Nelson, Viet Le, Jeffrey L. Anderson & Nicole Ciffone. (2024) Effect of statin add-on therapy on cardiovascular mortality. Frontiers in Cardiovascular Medicine 11.
Crossref
K. Vijayaraghavan, S. Baum, N. R. Desai & S. J. Voyce. (2024) Intermediate and long-term residual cardiovascular risk in patients with established cardiovascular disease treated with statins. Frontiers in Cardiovascular Medicine 10.
Crossref
Toru Miyoshi, Satoko Naoe, Hiroyuki Wakabayashi, Takashi Yano, Takuya Mori, Shingo Kanda, Makoto Arita & Hiroshi Ito. (2023) Enhanced Production of EPA-Derived Anti-Inflammatory Metabolites after Oral Administration of a Novel Self-Emulsifying Highly Purified EPA Ethyl Ester Formulation (MND-2119). Journal of Atherosclerosis and Thrombosis 30:12, pages 1927-1949.
Crossref
Snezana TepavcevicSnjezana RomicManja ZecTijana CulaficMojca StojiljkovicTamara IvkovicMarija PantelicMilan KosticJelena StanisicGoran Koricanac. (2023) Effects of Walnut-Rich Diet on Cation-Handling Proteins in the Heart of Healthy and Metabolically Compromised Male Rats. Journal of Medicinal Food 26:11, pages 849-857.
Crossref
Heinz Drexel, Juan Tamargo, Juan Carlos Kaski, Basil S Lewis, Christoph H Saely, Peter Fraunberger, Dobromir Dobrev, Maki Komiyama, Thomas Plattner, Stefan Agewall & Koji Hasegawa. (2023) Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?. European Heart Journal - Cardiovascular Pharmacotherapy 9:6, pages 570-582.
Crossref
Peter P. Toth, Jean Ferrières, Max Waters, Martin Bødtker Mortensen, Nick S. R. Lan & Nathan D. Wong. (2023) Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention. Frontiers in Cardiovascular Medicine 10.
Crossref
Viet T. Le, Stacey Knight, Jeramie D. Watrous, Mahan Najhawan, Khoi Dao, Raymond O. McCubrey, Tami L. Bair, Benjamin D. Horne, Heidi T. May, Joseph B. Muhlestein, John R. Nelson, John F. Carlquist, Kirk U. Knowlton, Mohit Jain & Jeffrey L. Anderson. (2023) Higher docosahexaenoic acid levels lower the protective impact of eicosapentaenoic acid on long-term major cardiovascular events. Frontiers in Cardiovascular Medicine 10.
Crossref
Kenneth T. Bogen. (2023) Ultrasensitive dose-response for asbestos cancer risk implied by new inflammation-mutation model. Environmental Research 230, pages 115047.
Crossref
Patrycja Szymańska, Bogusława Luzak, Katarzyna Miłowska & Jacek Golański. (2023) The Anti-Aggregative Potential of Resolvin E1 on Human Platelets. Molecules 28:14, pages 5323.
Crossref
Om P. Ganda, Robert Busch, J. R. Nelson & Sephy Philip. 2023. Lipoproteins in Diabetes Mellitus. Lipoproteins in Diabetes Mellitus 681 704 .
M. John Chapman, Jose L. Zamorano & Klaus G. Parhofer. (2022) Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Pharmacology & Therapeutics 237, pages 108172.
Crossref
Ashkan Shoamanesh & Magdy Selim. (2022) Use of Lipid-Lowering Drugs After Intracerebral Hemorrhage. Stroke 53:7, pages 2161-2170.
Crossref
Chiara Maria Soldavini, Gabriele Piuri, Gabriele Rossi, Paola Antonia Corsetto, Linda Benzoni, Valeria Maggi, Giulia Privitera, Angela Spadafranca, Angela Maria Rizzo & Enrico Ferrazzi. (2022) Maternal AA/EPA Ratio and Triglycerides as Potential Biomarkers of Patients at Major Risk for Pharmacological Therapy in Gestational Diabetes. Nutrients 14:12, pages 2502.
Crossref
Michael S. Garshick, Robert Block, Kamelia Drenkova, Michael Tawil, Genevieve James & J. Thomas Brenna. (2022) Statin therapy upregulates arachidonic acid status via enhanced endogenous synthesis in patients with plaque psoriasis. Prostaglandins, Leukotrienes and Essential Fatty Acids 180, pages 102428.
Crossref
Peter P. Toth, M. John Chapman, Klaus G. Parhofer & John R. Nelson. (2022) Differentiating EPA from EPA/DHA in cardiovascular risk reduction. American Heart Journal Plus: Cardiology Research and Practice 17, pages 100148.
Crossref
Luísa Martins Miller, Flávia Benetti Piccinin, Ubele van der Velden & Sabrina Carvalho Gomes. (2022) The Impact of Omega-3 Supplements on Non-Surgical Periodontal Therapy: A Systematic Review. Nutrients 14:9, pages 1838.
Crossref
Chen Luo & Zhenyue Chen. (2022) Is Omega-3 Index necessary for fish oil supplements for CVD risk prevention?. Cardiology Plus 7:2, pages 70-76.
Crossref
Margaret R. Diffenderfer, Nandani Rajapakse, Ericka Pham, Lihong He, Michael L. Dansinger, John R. Nelson & Ernst J. Schaefer. (2022) Plasma fatty acid profiles: Relationships with sex, age, and state-reported heart disease mortality rates in the United States. Journal of Clinical Lipidology 16:2, pages 184-197.
Crossref
Katarina Andelova, Barbara Szeiffova Bacova, Matus Sykora, Peter Hlivak, Miroslav Barancik & Narcis Tribulova. (2022) Mechanisms Underlying Antiarrhythmic Properties of Cardioprotective Agents Impacting Inflammation and Oxidative Stress. International Journal of Molecular Sciences 23:3, pages 1416.
Crossref
Arden R. Barry & Dave L. Dixon. (2021) Omega‐3 fatty acids for the prevention of atherosclerotic cardiovascular disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41:12, pages 1056-1065.
Crossref
Kenneth T. Bogen. (2022) Ultrasensitive Dose-Response for Asbestos Cancer Risk Implied by New Inflammation-Mutation Model. SSRN Electronic Journal.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.